ABSTRACT
Little new has been introduced into the armamentarium for asthma therapy in the last thirty years apart from improvements in b2-adrenoceptor agonists, corticosteroids and cysteinyl leukotriene antagonists. However, the introduction of a fully humanised monoclonal antibody to immunoglobulin E (IgE) (omalizumab), should provide a new way of treating